Gradient Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

Gradient Investments’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$828K	Buy	32,738 +3,838	+13%	+$84.4K	0.01%	339
2026 Q1	$643K	Buy	+28,900	New	+$691K	0.01%	333
2022 Q1	–	Sell	-86	Closed	-$2K	–	1163
2021 Q4	$2K	Buy	+86	New	+$1.73K	﹤0.01%	1044

Other funds holding ACAD

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $5.7B AUM 35.76% 1-Year Est. Return

Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

Gradient Investments's ACAD Position: Q2 2026 in Review

Gradient Investments increased its Acadia Pharmaceuticals (ACAD) stake by 13% in Q2 2026, buying an estimated $84.4K and bringing the position to 32,738 shares worth $828K. The position accounts for 0.01% of the portfolio, ranked #339.

Gradient Investments first reported a position in ACAD in Q4 2021 and has held it in 3 quarters since. 36 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Gradient Investments held 32,738 shares of Acadia Pharmaceuticals worth $828K as of Q2 2026.
Gradient Investments bought 3,838 Acadia Pharmaceuticals shares in Q2 2026, an estimated $84.4K.
Acadia Pharmaceuticals made up 0.01% of Gradient Investments's portfolio in Q2 2026, its #339 holding.
Gradient Investments first reported a position in Acadia Pharmaceuticals in Q4 2021 and has held it in 3 quarters since.
36 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Gradient Investments's 13F filing for Q2 2026, filed 8 Jul 2026.